Tourette Syndrome Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: May 26, 2026

Tourette syndrome — a childhood-onset neurodevelopmental disorder characterized by multiple motor and vocal tics — has a substantial genetic component, with heritability estimates from twin studies placing the inherited contribution at 50–70%. Variants near NR2F1, a transcription factor gene critical for cortical and subcortical neurodevelopment, emerged as the first genome-wide significant genetic signal for Tourette syndrome in a study of 6,133 affected individuals and 13,565 controls — with polygenic risk scores linking inherited genetic variation to structural differences in the thalamus and putamen, brain regions central to motor circuit regulation.^[3] Below: how inherited variation in neurodevelopmental biology shapes Tourette syndrome susceptibility, and what the research reveals about the genetics of this tic disorder.

What is Tourette syndrome?

Tourette syndrome is defined by the simultaneous presence of multiple motor tics and at least one vocal tic, persisting for more than one year, with onset before age 18. Motor tics are sudden, repetitive, stereotyped movements — eye blinking, head jerking, shoulder shrugging, facial grimacing. Vocal tics involve involuntary sounds — throat clearing, sniffing, humming, or in a minority of cases, words or phrases. Tics fluctuate in frequency and severity, typically waxing and waning over days to weeks, and generally peak in severity between ages 10 and 12.

Tourette syndrome lies within a spectrum of tic disorders. Provisional tic disorder involves tics present for less than one year; persistent motor or vocal tic disorder involves either motor or vocal tics — not both — lasting more than one year; Tourette syndrome requires both and the longer duration. TS is recognized clinically based on observation of the tic pattern over time, without requiring genetic testing or brain imaging. TS occurs approximately 3–4× more frequently in males than females and affects roughly 0.3–0.9% of school-age children.

The cortico-striato-thalamo-cortical (CSTC) circuit is the dominant neurobiological model for Tourette syndrome. In this circuit, the striatum (caudate and putamen) receives excitatory cortical input and sends inhibitory output through the globus pallidus to the thalamus, which projects back to the cortex. This circuit normally suppresses unwanted movements. In Tourette syndrome, dysregulation of this circuit — particularly disruption of striatal inhibitory signaling modulated by dopamine — is thought to allow repetitive motor programs to emerge as tics. The putamen and thalamus volumes associated with genetic risk scores in neuroimaging data directly implicate this circuit.

The genetics of Tourette syndrome

The genetic architecture of Tourette syndrome is highly polygenic — no single major-effect gene explains a substantial fraction of cases, and the heritable risk is distributed across many loci of small individual effect. Variants near NR2F1 at chromosome 5q15 and near COL27A1 at chromosome 9q32 appear in population-scale genetic studies of Tourette syndrome, alongside a broader landscape of neurodevelopmental loci.^[1][2][3]

6,133 individuals with Tourette syndrome and 13,565 ancestry-matched controls were analyzed in the largest dedicated TS genome-wide association study to date (Tsetsos et al. 2024, Biological Psychiatry), identifying a genome-wide significant locus at chromosome 5q15 implicating NR2F1 — and demonstrating that polygenic risk scores for Tourette syndrome associate with volumes of the right and left thalamus and the right putamen in neuroimaging analyses.^[3]

Variants near NR2F1 — nuclear receptor subfamily 2 group F member 1, also known as COUP-TFI — represent the current highest-confidence genetic signal for Tourette syndrome. NR2F1 is a transcription factor broadly involved in cortical arealization and subcortical neurodevelopment, including the development of thalamic and corticostriatal circuits during fetal and early postnatal brain formation. Its emergence as a TS susceptibility locus is mechanistically consistent with the CSTC circuit hypothesis: inherited variation in a gene shaping thalamic and corticostriatal connectivity during development could alter the inhibitory tone of the circuit that normally suppresses repetitive movements.

The first genome-wide association study of Tourette's syndrome, conducted in 1,285 cases and 4,964 controls, identified variants near COL27A1 on chromosome 9q32 as the top sub-threshold signal (Scharf et al. 2013, Molecular Psychiatry) — establishing the collaborative framework for TS genetics research and demonstrating that, like other neurodevelopmental conditions, Tourette syndrome requires very large sample sizes to achieve genome-wide resolution of its polygenic architecture.^[1]

Variants near COL27A1 — collagen type XXVII alpha 1, a fibrillar collagen expressed in cartilage, brain, and peripheral neuronal tissue — appeared as the top sub-threshold signal in the foundational TS GWAS. Extracellular matrix proteins including collagens are expressed in the developing brain and participate in neural circuit assembly, providing biological plausibility for ECM gene involvement in neurodevelopmental susceptibility. The broader genetic landscape of Tourette syndrome captured in multi-study reference data for this trait reflects the large number of loci with small individual effects that together constitute the polygenic architecture of TS risk across the genome.

What the research says

Research base: Robust. The genetic architecture of Tourette syndrome is supported by three genome-wide studies: the foundational TS GWAS in 1,285 cases (Scharf et al. 2013, Molecular Psychiatry);^[1] a meta-analytic investigation of Tourette's syndrome and other tic disorders (Yu et al. 2019, American Journal of Psychiatry);^[2] and the largest dedicated TS GWAS to date with 6,133 cases yielding the first genome-wide significant locus at 5q15 (Tsetsos et al. 2024, Biological Psychiatry).^[3] Robust confidence reflects the decade-long multi-study accumulation of genetic evidence and the first confirmed genome-wide significant signal for TS. An important note: Tourette syndrome genetics is at an earlier stage of discovery than most common disease GWAS — the field is still accumulating sample sizes needed to comprehensively map its polygenic architecture. See our methodology page for how we evaluate and apply genetic evidence in your ExomeDNA profile.

How Tourette syndrome genetics affects health

Tourette syndrome co-occurs with several neurodevelopmental and psychiatric conditions at rates substantially above background. Obsessive-compulsive disorder appears in approximately 30–50% of people with TS; attention deficit hyperactivity disorder appears in 50–60%. Anxiety and mood disorders are also more prevalent. The overlap between TS genetics and OCD/ADHD genetics reflects shared corticostriatal circuit biology — the same neural pathways implicated in tic generation are involved in the compulsive behavior circuits of OCD and the attentional dysregulation of ADHD.

A higher genetic risk score for Tourette syndrome reflects greater inherited susceptibility to developing TS — not certainty that tics will emerge or persist. Tic severity is substantially influenced by stress levels, sleep, developmental timing, and environmental factors. Many individuals with significant genetic susceptibility have mild tics that never require intervention; others never develop clinically apparent tics. The polygenic risk score reflects population-level tendency, not individual certainty of clinical presentation.

The association between polygenic risk scores and thalamus/putamen volumes in neuroimaging data from Tsetsos et al. 2024 provides mechanistic context: inherited genetic variation shapes the development of specific CSTC circuit structures, providing a link between genetics and brain anatomy underlying tic expression.

Working with your Tourette syndrome result

What research suggests about Tourette syndrome management

• Behavioral intervention: Comprehensive Behavioral Intervention for Tics (CBIT) is the first-line evidence-based treatment for TS — it teaches tic awareness and competing response strategies, with strong evidence for reducing tic frequency and severity without medication.^[3]
• Stress management: tic severity often increases with psychological stress and anxiety; stress reduction practices are important tic modifiers for many individuals with TS.
• Sleep adequacy: tics frequently worsen with sleep deprivation; consistent adequate sleep is among the most practical environmental modifiers of tic expression.
• OCD and ADHD awareness: given the co-occurrence rates, individuals aware of TS genetic susceptibility may benefit from monitoring for OCD tendencies and attention or executive function challenges.
• School and occupational accommodations: tics are often most prominent in structured environments; appropriate accommodations can substantially reduce functional impairment from tics that are otherwise mild.
• Family awareness: TS has high heritability — first-degree relatives of individuals with TS carry elevated genetic susceptibility; awareness supports early recognition and access to intervention if tics emerge.

Related traits and genes

Tourette syndrome risk connects closely to OCD Risk through shared corticostriatal circuit genetics — the same CSTC dysregulation underlying tic generation overlaps with the compulsive behavior circuits in OCD. ADHD Risk shares the highest comorbidity prevalence with TS and overlapping polygenic architecture reflecting shared neurodevelopmental biology. Anxiety Disorder Risk reflects the frequent co-occurrence of anxiety in TS populations and shared prefrontal-corticostriatal circuit involvement.

For brain biology, Cortical Brain Volume and Subcortical Volume Traits connect through the thalamic and putamen volume associations identified in TS polygenic risk score neuroimaging analyses. Dopamine Signaling Genetics is relevant to the dopaminergic mechanism of tic generation in the striatum, where dopamine modulates the inhibitory signaling implicated in TS.

Frequently asked questions

What is Tourette syndrome and how does it differ from other tic disorders?

Tourette syndrome requires both multiple motor tics and at least one vocal tic, persisting for more than one year with onset before age 18. Provisional tic disorder involves tics for less than one year; persistent motor or vocal tic disorder involves one tic type lasting more than one year. TS sits at the most complex end of the tic disorder spectrum and is most commonly associated with psychiatric comorbidities including OCD and ADHD. Tic types range from simple brief movements to complex sequences and fluctuate in severity over time.

What is NR2F1 and why does it appear in Tourette syndrome genetics?

NR2F1 (COUP-TFI) is a transcription factor that plays a key role in cortical arealization during brain development — it helps establish the functional organization of the cerebral cortex and connectivity of subcortical structures including the thalamus and striatum. Its emergence as the first genome-wide significant Tourette syndrome locus is consistent with the CSTC circuit model: inherited variation in a gene shaping thalamic and corticostriatal circuit development during early brain formation could alter the inhibitory architecture that normally suppresses repetitive movements, contributing to tic susceptibility across the population.

What brain regions are most affected in Tourette syndrome?

The cortico-striato-thalamo-cortical (CSTC) circuit is the central anatomical substrate. The striatum — specifically the caudate and putamen — receives cortical input and normally inhibits unwanted movement programs through the globus pallidus to the thalamus. Reduced inhibitory tone in this circuit is thought to allow repetitive motor programs to emerge as tics. The thalamus and putamen specifically — the regions whose volumes associate with Tourette syndrome polygenic risk scores in neuroimaging studies — are key nodes where inherited circuit biology translates into tic susceptibility.

Does a higher genetic risk score predict tic severity?

A higher genetic risk score reflects greater inherited susceptibility to developing Tourette syndrome — it is not a predictor of whether tics will emerge or how severe they will be. Many individuals with high genetic susceptibility have mild or transient tics; many develop no clinically apparent tics at all. Tic severity is influenced by stress, sleep, developmental timing, and environmental factors that interact with genetic background. The population-level genetic risk score is a tendency indicator, not an individual clinical forecast.

What is the connection between Tourette syndrome and OCD or ADHD?

OCD and ADHD are the most common comorbidities in Tourette syndrome — affecting approximately 30–50% and 50–60% of TS populations respectively. This overlap reflects shared corticostriatal circuit biology: the CSTC circuit implicated in tic generation overlaps with circuits involved in compulsive behavior (OCD) and executive function and attention (ADHD). Genetics research confirms this overlap through partial genetic correlation between polygenic risk scores for TS, OCD, and ADHD — pointing to shared inherited neurodevelopmental architecture rather than coincidental co-occurrence.

References

1. Scharf JM, et al. (2013). Genome-wide association study of Tourette's syndrome. Mol Psychiatry. PMID: 22889924. DOI: 10.1038/mp.2012.69.
2. Yu D, et al. (2019). Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. Am J Psychiatry. PMID: 30818990. DOI: 10.1176/appi.ajp.2018.18070857.
3. Tsetsos F, et al. (2024). Genome-Wide Association Study Points to Novel Locus for Gilles de la Tourette Syndrome. Biol Psychiatry. PMID: 36738982. DOI: 10.1016/j.biopsych.2023.01.023.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
• Open Targets Platform (CC0 1.0, accessed 2026-05-26)
• ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-26.